


## Lofepramine

<b>Cat. No.:</b>	HY-12390		
<b>CAS No.:</b>	23047-25-8		
<b>Molecular Formula:</b>	C <sub>26</sub> H <sub>27</sub> ClN <sub>2</sub> O		
<b>Molecular Weight:</b>	418.96		
<b>Target:</b>	Others		
<b>Pathway:</b>	Others		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 50 mg/mL (119.34 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.3869 mL	11.9343 mL	23.8686 mL
	5 mM	0.4774 mL	2.3869 mL	4.7737 mL
	10 mM	0.2387 mL	1.1934 mL	2.3869 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: 2.08 mg/mL (4.96 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.08 mg/mL (4.96 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

Lofepramine (Lopramine) is a potent tricyclic antidepressant and is extensively metabolised to Desipramine. The antidepressant activity of Lofepramine stems from the facilitation of noradrenergic neurotransmission by uptake inhibition. Lofepramine may also potentiate serotonergic neurotransmission by inhibition of the neuronal uptake of serotonin and the enzyme tryptophan pyrrolase. Lofepramine has significant anxiolytic efficacy in addition to its antidepressant properties [1].

### REFERENCES

---

[1]. Lancaster SG, et al. Lofepamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. *Drugs*. 1989 Feb;37(2):123-40.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA